

**Neumora Therapeutics, Inc.**  
490 Arsenal Way, Suite 200  
Watertown, Massachusetts 02472

September 12, 2023

**VIA EDGAR AND E-MAIL**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-6010

Attention: Eric Atallah  
Al Pavot  
Daniel Crawford  
Laura Crotty

**Re: Neumora Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-274229)**

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-274229) (the “**Registration Statement**”) of Neumora Therapeutics, Inc. (the “**Company**”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 14, 2023, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Phillip Stoup at (415) 395-8216 or B. Shayne Kennedy at (714) 755-8181.

Thank you for your assistance in this matter.

Very truly yours,

**NEUMORA THERAPEUTICS, INC.**

By: /s/ Henry O. Gosebruch  
Henry O. Gosebruch  
President and Chief Executive Officer

cc: Paul L. Berns, Neumora Therapeutics, Inc.  
Phillip Stoup, Latham & Watkins LLP  
B. Shayne Kennedy, Latham & Watkins LLP  
Charles S. Kim, Cooley LLP  
Kristin VanderPas, Cooley LLP  
Dave Peinsipp, Cooley LLP  
Denny Won, Cooley LLP